What to Look for in a Biotech Building: A Practical Guide

Finding the right building for a biotech or life sciences company is a fundamentally different exercise than a standard office search. The physical infrastructure has to work before anything else can — and most commercial buildings aren’t built for what biotech tenants actually need.

This guide covers what matters when evaluating a biotech building: the infrastructure requirements, the compliance considerations, the questions brokers don’t always think to ask, and the factors that determine whether a space actually works for laboratory and R&D operations.

Laboratory Infrastructure: The Foundation of Everything

The most important thing to understand about biotech real estate is that standard commercial office buildings — even Class A properties — typically can’t support wet lab operations without significant modification. The infrastructure gap between a standard office and a functional lab environment is wide and expensive to close.

Ceiling height and structural capacity

Wet lab operations require minimum clear heights of 12–14 feet to accommodate ventilation systems, ductwork, and equipment installation. Many commercial buildings top out at 9–10 feet of clear height, which eliminates them before any other evaluation takes place. Floor load capacity is equally important — heavy analytical equipment, centrifuges, and storage systems require reinforced floors that not every building can accommodate without structural modification.

HVAC and ventilation

Lab environments require 100% outside air systems with high air change rates — typically 6–12 air changes per hour for a BSL-1 or BSL-2 lab, compared to 4–6 for standard office space. Standard commercial HVAC systems are not designed for this and generally cannot be retrofitted without significant capital investment. Confirming the building’s HVAC capacity and airflow design is one of the first things to establish in any lab site evaluation.

Electrical capacity

Biotech tenants typically require 3–4 times the electrical capacity of a standard office tenant. High-throughput analytical instruments, freezer banks, centrifuges, and biosafety cabinets all draw substantial power. Confirm available amperage and transformer capacity before going further in any evaluation — upgrading electrical infrastructure mid-lease is expensive and disruptive.

Specialized utilities

Beyond standard utilities, most wet lab operations require:

• Deionized or purified water systems
• Compressed air and vacuum lines
• Gas lines — natural gas, nitrogen, CO₂, or oxygen depending on application
• Chemical waste drainage systems with acid neutralization where required
• Emergency eyewash and safety shower stations

Buildings with these systems already in place dramatically reduce build-out cost and timeline. Buildings without them aren’t necessarily disqualified, but the cost of installing them needs to be reflected in the tenant improvement negotiation.

Biosafety and Regulatory Compliance

Biotech facilities must meet specific biosafety requirements depending on the type of research being conducted. Understanding which biosafety level your operations require — and confirming that a building can support it — is non-negotiable before signing a lease.

BSL-1 and BSL-2 are the most common classifications for commercial biotech tenants. BSL-1 covers work with non-pathogenic organisms and requires basic containment — handwashing facilities, personal protective equipment, and standard waste disposal. BSL-2 involves agents that pose moderate hazards and requires additional containment measures including restricted access, sharps protocols, and enhanced waste handling.

BSL-3 facilities — required for work with serious or potentially lethal agents — involve significant additional infrastructure requirements including negative pressure rooms, HEPA filtration, and dedicated ventilation systems. Very few commercial buildings are built or adapted for BSL-3 operations without substantial investment.

Beyond biosafety classification, buildings housing biotech operations must also meet OSHA requirements for hazardous chemical storage, chemical waste disposal regulations, and any applicable EPA or local environmental permitting requirements. Confirming the zoning classification and permitted use for the specific building and municipality is an essential early step — not every commercially zoned property is approved for laboratory or research use.

Location and Ecosystem Access

Location matters for biotech companies in ways that go beyond commute time and neighborhood preference.

Proximity to research institutions
Being near universities, research hospitals, and established life sciences clusters accelerates access to talent, research partnerships, and collaboration opportunities. San Francisco’s Mission Bay, South San Francisco, and Torrance in Los Angeles are examples of submarkets where institutional proximity has driven sustained demand from biotech tenants.

Access to the talent pool
Biotech companies compete for a specialized workforce — molecular biologists, biochemists, lab technicians, clinical researchers. Proximity to the universities and graduate programs that produce that talent is a meaningful factor in long-term operational success and hiring cost.

Supply chain and logistics
For companies involved in clinical trials, manufacturing, or regular shipment of biological materials, proximity to major transportation infrastructure — airports, freight hubs, and major highways — reduces cost and complexity. Loading dock access and freight elevator availability within the building itself are details that matter on day one of operations.

Scalability and Flexibility

Biotech companies grow fast when programs advance. A facility that works for a 20-person research team may be inadequate within 18 months if a clinical milestone is hit or a fundraise closes. Evaluating a building’s ability to accommodate growth is as important as evaluating its current fit.

Key considerations include:

• Expansion rights — does the building have adjacent space, or rights of first refusal on neighboring suites, that can be exercised as headcount grows?
• Flexible floor plates — can the space be reconfigured as team composition evolves between wet lab, dry lab, and office use?
• Shell space availability — some life sciences campuses have unfinished shell space that can be built out to specific requirements as companies grow

The alternative to planning for scalability is relocation — which for a biotech tenant with installed lab infrastructure is expensive, operationally disruptive, and time-consuming to execute.

The Tenant Improvement Negotiation

Lab build-outs are expensive. For wet lab space, costs typically run $150–$300+ per square foot depending on the scope, the existing infrastructure, and the market. That makes the tenant improvement allowance negotiation one of the most consequential parts of any biotech lease.

A few things to understand going in:

What landlords typically cover: structural systems, core HVAC modifications, electrical upgrades to the panel, and base plumbing. These are capital improvements that stay with the building.

What typically falls to the tenant: specialized lab casework, fume hoods, biosafety cabinets, gas distribution systems, specialized flooring, and equipment. These are tenant-specific improvements.

The gray zone: items like DI water systems, additional ventilation drops, and enhanced electrical distribution can go either way depending on the landlord’s appetite and the term length being negotiated. Longer leases give tenants more leverage to push more of the build-out cost onto the landlord.

Landlords who have done biotech build-outs before understand the economics. Those who haven’t may need more education — or may not be the right partners for a complex life sciences tenant.

Security and Data Protection

Biotech companies hold some of the most valuable intellectual property in any industry — research data, proprietary formulations, clinical trial results, and compound libraries. Physical and digital security deserve more attention than they typically get in lease negotiations.

Physical security: access control systems that restrict entry to sensitive lab areas, secure storage for biological samples and proprietary materials, and camera coverage of high-value areas are baseline requirements. Confirm what the building provides and what falls to the tenant to install.

Data security: for companies handling patient data, clinical trial information, or research subject to export controls, the building’s network infrastructure and data handling capabilities matter. Cybersecurity protocols, secure data storage, and compliance with HIPAA or other applicable frameworks should be evaluated alongside the physical facility.

Frequently Asked Questions

What makes a building suitable for biotech use?
A biotech-suitable building has adequate ceiling height (minimum 12–14 feet clear), enhanced electrical capacity, HVAC systems capable of supporting required air change rates, appropriate utility infrastructure (DI water, gas lines, chemical drainage), and zoning that permits laboratory or research use. Buildings with these features already in place significantly reduce build-out cost and timeline.

What is the difference between wet lab and dry lab space?
A wet lab involves physical or chemical experiments requiring specialized infrastructure — ventilation, plumbing, gas lines, and containment systems. A dry lab is a computational environment that resembles standard office space with higher power and connectivity requirements. Many biotech companies need both, and the ratio between them shifts as companies progress through development stages.

How much does it cost to build out a biotech lab?
Wet lab build-out costs typically range from $150 to $300+ per square foot depending on scope, existing infrastructure, and market. This is significantly higher than standard office build-outs and makes the tenant improvement allowance one of the most important variables in any biotech lease negotiation.

What biosafety level do I need for my facility?
It depends on the organisms or materials your research involves. Most early-stage biotech companies operate at BSL-1 or BSL-2. BSL-3 involves significantly more complex infrastructure requirements and is less common in commercial facilities. Your biosafety officer or a qualified consultant should determine the appropriate classification before you begin your space search.

How long does a biotech lease build-out take?
For a full wet lab build-out, expect 6–12 months from lease execution to occupancy, depending on permit timelines and construction complexity. Buildings with existing lab infrastructure can reduce this significantly. This timeline should factor into any company planning a move — starting the search earlier than feels necessary is almost always the right call.

Finding the right biotech building requires knowing what to look for before you start touring — and knowing which questions to ask before you sign anything. If you’re evaluating lab or office space for a life sciences company in San Francisco or Los Angeles, we’re happy to walk through what the market looks like and what your specific operations actually require.